Document is current
Any future updates will be listed below
-
Authors
Ostor, Andrew J K https://orcid.org/0000-0002-7929-4827
Soliman, Ahmed M
Papp, Kim A
Padilla, Byron
Wang, Zailong
Eldred, Ann
de Vlam, Kurt
Kivitz, Alan
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03671148 at ClinicalTrials.govnct03671148 at ClinicalTrials.govDocuments that mention this clinical trial
Improved patient-reported outcomes in patients with psoriatic arthritis treated with risankizumab: analysis of the Phase 3 trial KEEPsAKE 2
https://doi.org/10.1136/rmdopen-2022-002286
Enthesitis and Dactylitis Resolution with Risankizumab for Active Psoriatic Arthritis: Integrated Analysis of the Randomized KEEPsAKE 1 and 2 Trials
https://doi.org/10.1007/s13555-024-01174-4
OP0228 EFFICACY AND SAFETY OF RISANKIZUMAB FOR ACTIVE PSORIATIC ARTHRITIS, INCLUDING PATIENTS WITH INADEQUATE RESPONSE OR INTOLERANCE TO BIOLOGIC THERAPIES: 24-WEEK RESULTS FROM THE PHASE 3, RANDOMIZED, DOUBLE-BLIND, KEEPSAKE 2 TRIAL
https://doi.org/10.1136/annrheumdis-2021-eular.2695
Efficacy of risankizumab across GRAPPA domains in psoriatic arthritis: a pooled analysis of patients from the phase 3 KEEPsAKE 1 and 2 studies
https://doi.org/10.1136/rmdopen-2025-005522
AB0905 Routine Assessment of Patient Index Data 3 (RAPID3) in Patients With Active Psoriatic Arthritis (PsA) After Inadequate Response or Intolerance to DMARDs: Pooled Results From the Phase 3, Randomized, Double-Blind KEEPsAKE 1 and 2 Trials
https://doi.org/10.1136/annrheumdis-2022-eular.2913
POS1036 EFFICACY AND SAFETY OF RISANKIZUMAB (RZB) FOR ACTIVE PSORIATIC ARTHRITIS (PsA): 52-WEEK RESULTS FROM KEEPsAKE 2
https://doi.org/10.1136/annrheumdis-2022-eular.1673
POS1545 MODULATION OF SERUM BIOMARKERS IN PATIENTS WITH PSA TREATED WITH RISANKIZUMAB IN THE PHASE 3 KEEPSAKE 2 STUDY
https://doi.org/10.1136/annrheumdis-2023-eular.3927
POS1524 DURABLE CLINICALLY-MEANINGFUL IMPROVEMENTS IN HEALTH-RELATED QUALITY OF LIFE, FATIGUE, PAIN, AND WORK PRODUCTIVITY AMONG PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS TREATED WITH RISANKIZUMAB AT WEEK 100
https://doi.org/10.1136/annrheumdis-2023-eular.3268
POS1057 IMPACT OF RISANKIZUMAB ON ENTHESITIS AND ASSOCIATED PAIN: POOLED RESULTS FROM THE PHASE 3, RANDOMIZED, DOUBLE-BLIND KEEPsAKE 1 AND 2 TRIALS
https://doi.org/10.1136/annrheumdis-2022-eular.3161
Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 2 trial
https://doi.org/10.1136/annrheumdis-2021-221048
Population Pharmacokinetics and Exposure–Response Analyses for Risankizumab in Patients with Active Psoriatic Arthritis
https://doi.org/10.1007/s40744-022-00495-0
AB0957 IMPROVEMENTS IN PATIENT-REPORTED OUTCOMES AMONG PATIENTS WITH RESOLUTION OF ENTHESITIS AND/OR DACTYLITIS: POST HOC ANALYSES FROM THE KEEPSAKE 1 AND 2 TRIALS OF RISANKIZUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS
https://doi.org/10.1136/annrheumdis-2023-eular.2790
POS1032 RISANKIZUMAB FOR ACTIVE PSORIATIC ARTHRITIS: INTEGRATED SUBGROUP ANALYSIS FROM 2 DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDIES (KEEPsAKE 1 AND KEEPsAKE 2)
https://doi.org/10.1136/annrheumdis-2022-eular.1390
Comparative Effectiveness of Bimekizumab and Risankizumab in Patients with Psoriatic Arthritis at 52 Weeks Assessed Using a Matching-Adjusted Indirect Comparison
https://doi.org/10.1007/s40744-024-00706-w
Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 196-Week Results from the KEEPsAKE 1 and KEEPsAKE 2 Randomized Clinical Trials
https://doi.org/10.1007/s40744-025-00793-3
Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 1 trial
https://doi.org/10.1136/annrheumdis-2021-221019
Documents that mention this clinical trial
Improved patient-reported outcomes in patients with psoriatic arthritis treated with risankizumab: analysis of the Phase 3 trial KEEPsAKE 2
https://doi.org/10.1136/rmdopen-2022-002286
Enthesitis and Dactylitis Resolution with Risankizumab for Active Psoriatic Arthritis: Integrated Analysis of the Randomized KEEPsAKE 1 and 2 Trials
https://doi.org/10.1007/s13555-024-01174-4
OP0228 EFFICACY AND SAFETY OF RISANKIZUMAB FOR ACTIVE PSORIATIC ARTHRITIS, INCLUDING PATIENTS WITH INADEQUATE RESPONSE OR INTOLERANCE TO BIOLOGIC THERAPIES: 24-WEEK RESULTS FROM THE PHASE 3, RANDOMIZED, DOUBLE-BLIND, KEEPSAKE 2 TRIAL
https://doi.org/10.1136/annrheumdis-2021-eular.2695
Efficacy of risankizumab across GRAPPA domains in psoriatic arthritis: a pooled analysis of patients from the phase 3 KEEPsAKE 1 and 2 studies
https://doi.org/10.1136/rmdopen-2025-005522
AB0905 Routine Assessment of Patient Index Data 3 (RAPID3) in Patients With Active Psoriatic Arthritis (PsA) After Inadequate Response or Intolerance to DMARDs: Pooled Results From the Phase 3, Randomized, Double-Blind KEEPsAKE 1 and 2 Trials
https://doi.org/10.1136/annrheumdis-2022-eular.2913
POS1036 EFFICACY AND SAFETY OF RISANKIZUMAB (RZB) FOR ACTIVE PSORIATIC ARTHRITIS (PsA): 52-WEEK RESULTS FROM KEEPsAKE 2
https://doi.org/10.1136/annrheumdis-2022-eular.1673
POS1545 MODULATION OF SERUM BIOMARKERS IN PATIENTS WITH PSA TREATED WITH RISANKIZUMAB IN THE PHASE 3 KEEPSAKE 2 STUDY
https://doi.org/10.1136/annrheumdis-2023-eular.3927
POS1524 DURABLE CLINICALLY-MEANINGFUL IMPROVEMENTS IN HEALTH-RELATED QUALITY OF LIFE, FATIGUE, PAIN, AND WORK PRODUCTIVITY AMONG PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS TREATED WITH RISANKIZUMAB AT WEEK 100
https://doi.org/10.1136/annrheumdis-2023-eular.3268
POS1057 IMPACT OF RISANKIZUMAB ON ENTHESITIS AND ASSOCIATED PAIN: POOLED RESULTS FROM THE PHASE 3, RANDOMIZED, DOUBLE-BLIND KEEPsAKE 1 AND 2 TRIALS
https://doi.org/10.1136/annrheumdis-2022-eular.3161
Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 2 trial
https://doi.org/10.1136/annrheumdis-2021-221048
Population Pharmacokinetics and Exposure–Response Analyses for Risankizumab in Patients with Active Psoriatic Arthritis
https://doi.org/10.1007/s40744-022-00495-0
AB0957 IMPROVEMENTS IN PATIENT-REPORTED OUTCOMES AMONG PATIENTS WITH RESOLUTION OF ENTHESITIS AND/OR DACTYLITIS: POST HOC ANALYSES FROM THE KEEPSAKE 1 AND 2 TRIALS OF RISANKIZUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS
https://doi.org/10.1136/annrheumdis-2023-eular.2790
POS1032 RISANKIZUMAB FOR ACTIVE PSORIATIC ARTHRITIS: INTEGRATED SUBGROUP ANALYSIS FROM 2 DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDIES (KEEPsAKE 1 AND KEEPsAKE 2)
https://doi.org/10.1136/annrheumdis-2022-eular.1390
Comparative Effectiveness of Bimekizumab and Risankizumab in Patients with Psoriatic Arthritis at 52 Weeks Assessed Using a Matching-Adjusted Indirect Comparison
https://doi.org/10.1007/s40744-024-00706-w
Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 196-Week Results from the KEEPsAKE 1 and KEEPsAKE 2 Randomized Clinical Trials
https://doi.org/10.1007/s40744-025-00793-3
Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 1 trial
https://doi.org/10.1136/annrheumdis-2021-221019
-
Funding
Funding for this research was provided by:
AbbVie Inc
- License Information
